Supporting Information

Tumor-targeting Polycaprolactone nanoparticles with co-delivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer

Qianqian Pan¹,², Jingjun Tian¹, Huihui Zhu¹, Liangjie Hong³, Zhengwei Mao³*, Joaquim Miguel Oliveira⁴,⁵,⁶, Rui L. Reis⁴,⁵,⁶, Xiao Li¹*

¹Women’s Reproductive Health Laboratory of Zhejiang Province, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China
²Zhejiang Financial College, No.118 Xueyuan Street, 310018 Hangzhou, Zhejiang, China.
³MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, P. R. China
⁴3B’s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Zona Industrial da Gandra, 4805-017 Barco GMR, Portugal
⁵ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
⁶The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, 4805-017 Barco, Guimarães, Portugal
**Figure S1.** TEM images of (A) PCL and (B) PCL/IR780-PTX nanoparticles.

**Figure S2.** The temperature of 0.5 mg/mL PCL-LHRH/IR780-PTX nanoparticle suspension as a function of irradiation time under different light dosage.
Figure S3. Fluorescent intensity of endothelial cells cultured with Nile red-labelled PCL NPs or PCL-LHRH NPs, as a function of incubation time.

Figure S4. Plasma ID% of IR780 in tumor bearing mice as a function of time after administration of free IR780, PCL/IR780 and IR780-LHRH/IR780, respectively.
**Figure S5.** Photos of ST30 tumors harvested from mice after sacrifice. Circles indicate that there is no tumor left.

**Figure S6.** The density of proliferative (Ki67 positive) cells. ** indicates significant difference at p<0.01 level. (I) control group, (II) PTX + Light group, (III) PCL-LHRH/IR780-PTX NPs, (IV) PCL-LHRH/IR780 + Light, (V) PCL/IR780-PTX + Light, and (VI) PCL-LHRH/IR780-PTX + Light, respectively (n = 5).
Figure S7. Blood test results of mice received (I) PCL-LHRH NPs and (II) PCL-LHRH/IR780-PTX NPs (n=4). The blood was collected and tested after 1 day after i.v. injection of nanoparticles. The dosages of PCL-LHRH NPs and IR780 were 2 mg and 148 μg for each mouse, respectively.